Lupin Appoints Akhil Gupta as Additional Director

Mumbai : Global pharmaceutical company Lupin Limited has appointed Akhil Gupta as an Additional Director (Non-Executive, Independent) to its Board, with effect from November 3, 2026. He will serve as an Independent Director for a term of five consecutive years, from November 3, 2026, to November 2, 2031, subject to the approval of the company's members. The appointment was approved unanimously by the Board of Directors at its meeting held on November 3, 2026, following the recommendation of the Nomination and Remuneration Committee. According to the regulatory filing, Lupin confirmed that, based on the information available with the company, Akhil Gupta is not debarred from holding the office of Director under any order passed by SEBI or any other authority. Gupta is a qualified Chartered Accountant with over four decades of professional experience. He has also completed the Advanced Management Program from Harvard Business School at Harvard University, Boston, Massachusetts. His professional experience spans business development, corporate strategy, finance, governance and mergers and acquisitions. He currently serves as the Non-Executive Independent Chairman of 360 ONE WAM Limited, Coforge Limited and Valuedrive Technologies Limited (Spinny). He is also an Independent Director on the boards of Lodha Developers Limited and Zepto Limited, and serves as a Nominee Director of Acevector Limited. In addition to his corporate responsibilities, Gupta is the President of the Telecom Sector Skill Council. He is a former Chairman of the Digital Infrastructure Providers Association and a member of the Confederation of Indian Industry (CII) National Committee on Telecom and Broadband and the CII Task Force on Insolvency and Bankruptcy. He has also been a member of the Advisory Committee on Service Providers of the Insolvency and Bankruptcy Board of India and the Sub-Committee of the Insolvency Law Committee, Government of India. Gupta is also the Chairman of Inversion Advisory Services, where he advises several prominent companies across diverse sectors, including infrastructure, renewable energy, automobiles, tourism, consulate services and footwear. Earlier, he served as the Vice Chairman of Bharti Enterprises Limited, where he played a significant role in the group's growth from its inception through organic expansion and various acquisitions. During his professional career, Gupta has received several prestigious recognitions, including the Tele.Net Outstanding Contribution to Infrastructure and Telecom Development Award and Lifetime Achievement Awards from ET Telecom, Voice & Data, the Institute of Chartered Accountants of India (ICAI) and Amity University. His other honours include the EY Entrepreneur of the Year Award in the Entrepreneur CEO category, CA Global Achiever Award, CA Business Achiever Award, CEO of the Year Award, Asia Corporate Dealmaker Award, multiple CNBC-TV18 Best CFO Awards and induction into the CFO India Hall of Fame. Commenting on the appointment, Manju D. Gupta, Chairperson of Lupin, said, "We are delighted to welcome Akhil to the Lupin Board. He brings a rare combination of strategic perspective, financial acumen, governance experience, and a proven track record of building businesses at scale. His counsel will be valuable as Lupin continues to strengthen its global position and pursue its next phase of growth." The company also disclosed that Akhil Gupta is not related to any of the directors, Key Managerial Personnel or promoters of Lupin Limited. Headquartered in Mumbai, Lupin Limited has a presence across India, the United States, other developed markets and emerging markets, with its products distributed in more than 100 markets. Its diversified portfolio includes generics, complex generics, specialty medicines and biosimilars. The company has a strong presence in cardiovascular, respiratory, diabetes, gastrointestinal and women's health therapeutic areas. Its operations are supported by 15 state-of-the-art manufacturing facilities, six research centres and a workforce of more than 26,000 professionals. Lupin also operates across diagnostics, digital health, patient-support programmes and disease management initiatives, with sustainability forming a core part of its business strategy. Also Read: Lupin Gets USFDA Nod for Modafinil Tablets Used to Treat Excessive Sleepiness